- Mesoblast receives regulatory clearance to begin Phase 2 trial for wet Age-related Macular Degeneration (AMD)
- Trial will be performed at Singapore National Eye Centre, combining Mesoblast's allogeneic ("off-the-shelf") cells with anti-VEGF agent
- Wet AMD, the leading cause of blindness in industrialized countries, has different forms in Asia and North America/ Europe
- Anti-VEGF agents are less effective in Asian form of wet AMD
- Mesoblast's allogeneic cells may be effective for both Asian and North American/European forms of wet AMD
- Commencing this trial in Singapore is in line with Mesoblast's evolving clinical and manufacturing strategies
Mesoblast Cleared To Begin First Phase 2 Clinical Trial For Eye Diseases
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.